The House and Senate proposals to reform the pharmacy benefits management industry are looking more alike following a House Energy and Commerce health subcommittee markup this month, but prospects for 2023 clearance of this legislation is looking increasingly slim.
Rx Rebating Bills In House, Senate Come Into Alignment As Passage Likely Punted to 2024
Legislation to delink PBM payments from drug prices advances in House Energy and Commerce health subcommittee, putting a key pharma priority closer to the finish line. Whether patients will see any benefit remains a worry.

More from Legislation
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
Republican congressional staffers could bring a wealth of experience and strong contacts with key legislators to the FDA ahead of the next user fee reauthorization process. But will Health and Human Services Department leadership interfere?
Not all companies will be able to access joint scientific consultations under the EU Health Technology Assessment Regulation, but success is still possible for those that engage with national agencies early on, says EUCOPE’s Alexander Natz.
The Clinical Trials Regulation was “supposed to harmonize” requirements in the EU, but instead it is giving some countries the chance to get ahead by offering faster approval timelines, notes Telethon’s head of regulatory affairs.
More from Pink Sheet
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.